Oxaliplatin and 5-Fluorouracil for Colorectal Cancer
Author Information
Author(s): Chau I, Webb A, Cunningham D, Hill M, Waters J S, Norman A, Massey A
Primary Institution: Royal Marsden Hospital
Hypothesis
The study aimed to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed colorectal cancer.
Conclusion
Oxaliplatin and PVI 5-FU is an active and well-tolerated treatment for patients with heavily pre-treated advanced colorectal cancer.
Supporting Evidence
- The best achieved objective tumor response rate was 29%.
- 52.6% of patients had stable disease after treatment.
- The median duration of response was 3.9 months.
- The median survival was 9.1 months.
- Probability of overall survival at 6 months was 58.4%.
Takeaway
This study tested a new treatment for patients with advanced colon cancer and found it helped some people feel better and live longer.
Methodology
Patients received oxaliplatin every 2 weeks and PVI 5-FU daily, with a median follow-up of 6.1 months.
Limitations
The study had a small sample size and was limited to patients who had already been treated with other therapies.
Participant Demographics
Median age of patients was 61 years; 17 had more than 2 sites of disease involvement.
Statistical Information
Confidence Interval
95% CI = 15–46% for tumor response rate; 95% CI = 38.7–73.7% for overall survival at 6 months.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website